Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT7001 (Samuraciclib) Alone and in Combination With Anti-cancer Treatments in Advanced Malignancies
NCT03363893Phase 2Completed
- Sponsor
- Carrick Therapeutics
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of samuraciclib in solid tumor, breast cancer, prostate cancer (PCa), sponsored by Carrick Therapeutics. Started Nov 2017; status: completed.
02
Drugs
samuraciclib
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03363893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363893.